CN111658819A - Triblock hydrogel copolymer with temperature response and preparation method thereof - Google Patents
Triblock hydrogel copolymer with temperature response and preparation method thereof Download PDFInfo
- Publication number
- CN111658819A CN111658819A CN202010587547.1A CN202010587547A CN111658819A CN 111658819 A CN111658819 A CN 111658819A CN 202010587547 A CN202010587547 A CN 202010587547A CN 111658819 A CN111658819 A CN 111658819A
- Authority
- CN
- China
- Prior art keywords
- copolymer
- hydrogel
- temperature
- group
- triblock
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 74
- 229920001577 copolymer Polymers 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000178 monomer Substances 0.000 claims abstract description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 16
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 14
- 235000020638 mussel Nutrition 0.000 claims abstract description 14
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002105 nanoparticle Substances 0.000 claims abstract description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000004873 anchoring Methods 0.000 claims abstract description 7
- 229910052709 silver Inorganic materials 0.000 claims abstract description 7
- 239000004332 silver Substances 0.000 claims abstract description 7
- 230000003592 biomimetic effect Effects 0.000 claims description 13
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 10
- 230000036760 body temperature Effects 0.000 claims description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical group NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical group [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229960003638 dopamine Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 3
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 3
- 239000003999 initiator Substances 0.000 claims description 3
- 229960003151 mercaptamine Drugs 0.000 claims description 3
- 238000012712 reversible addition−fragmentation chain-transfer polymerization Methods 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 2
- 239000012990 dithiocarbamate Substances 0.000 claims description 2
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical group C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 2
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical group NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 45
- 206010052428 Wound Diseases 0.000 abstract description 43
- 230000035876 healing Effects 0.000 abstract description 13
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 11
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 238000005507 spraying Methods 0.000 abstract description 4
- 239000003106 tissue adhesive Substances 0.000 abstract description 4
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 230000000379 polymerizing effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 description 16
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 10
- 229930105110 Cyclosporin A Natural products 0.000 description 10
- 108010036949 Cyclosporine Proteins 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域technical field
本发明属于水凝胶材料技术领域,具体涉及一种具有温度响应的三嵌段水凝胶共聚物及其制备方法。The invention belongs to the technical field of hydrogel materials, in particular to a temperature-responsive triblock hydrogel copolymer and a preparation method thereof.
背景技术Background technique
烧伤是一种由来源于包括热液、高温气体、火焰、炽热金属、化学物质等多种热力引起的组织损坏,主要发生于皮肤、粘膜等体表组织。机会出现严重的烧伤之后,除了区域性的皮肤粘膜局部损伤,还会产生以下反应:新陈代谢增加、体温下降、水分过度散失、蛋白质大量丢失以及内分泌和免疫系统的失调。其中暴露的烧伤创面,除了在短时间内会造成机体体液平衡紊乱、防御屏障的破坏之外,长期不愈合的创面还会成为细菌定植生长的温床。因此在烧伤发生后,尤其是大面积烧伤中,使用敷料覆盖创面,临时作为体表保护屏障,防止细菌的进一步入侵,促进创面愈合,就显得至关重要。Burn is a kind of tissue damage caused by a variety of heat sources including hydrothermal fluids, high-temperature gases, flames, hot metals, and chemicals. It mainly occurs in surface tissues such as skin and mucous membranes. Opportunity for severe burns, in addition to local skin and mucous membrane local damage, the following reactions will occur: increased metabolism, decreased body temperature, excessive loss of water, massive loss of protein, and disorders of the endocrine and immune systems. The exposed burn wounds will not only cause disturbance of the body's fluid balance and damage to the defense barrier in a short period of time, but also the long-term non-healing wounds will become a breeding ground for bacterial colonization and growth. Therefore, after the occurrence of burns, especially in large-area burns, it is very important to use dressings to cover the wound surface to temporarily serve as a protective barrier on the body surface to prevent further invasion of bacteria and promote wound healing.
目前临床上针对烧伤创面大多使用的传统医用敷料,是以纱布、棉垫为主,其具有吸水性和一定的透气性,另外该传统医用敷料制作流程简单,价格便宜,可重复使用。但是传统敷料保湿效果不佳,且自身不具备抗菌能力,与此同时,还会出现敷料移位、脱落;更换伤口敷料时,因纱布干结、肉芽组织生长出现与创面的粘连,造成病人疼痛、出血等二次损伤。如何通过医用敷料促进深度的烧伤创面局部组织的再生和修复,逐渐引起临床医生的关注。已有研究得出,适宜的组织再生环境包括一定的湿度、温度和无菌条件。因此理想的敷料应具备吸收创面渗液、保持创面湿度温度、一定的透气性和抗菌能力等特点,从而促进创面愈合。At present, most of the traditional medical dressings used clinically for burn wounds are mainly gauze and cotton pads, which have water absorption and certain air permeability. In addition, the traditional medical dressings are simple in production process, inexpensive and reusable. However, the traditional dressings have poor moisturizing effect and do not have antibacterial ability. At the same time, the dressings will shift and fall off. When the wound dressings are replaced, the gauze is dry and the granulation tissue grows and adheres to the wound surface, causing pain, Bleeding and other secondary injuries. How to promote the regeneration and repair of local tissue in deep burn wounds through medical dressings has gradually attracted the attention of clinicians. Existing studies have concluded that a suitable tissue regeneration environment includes certain humidity, temperature and sterile conditions. Therefore, the ideal dressing should have the characteristics of absorbing wound exudate, maintaining the humidity and temperature of the wound, certain air permeability and antibacterial ability, so as to promote wound healing.
人们早就发现合成材料有助于促进皮肤创伤的愈合。1962年,伦敦大学的Winter博士在Nature杂志上发表著名论文,论证了湿润环境对创面的愈合作用:与用聚乙烯膜封闭猪断层皮肤缺损创面相比,暴露在空气中的创面再上皮化概率增加50%(Nature.1962;193:293-4)。Pulat等(Polymer edition.2013;24(7):807-819)以乙二醇二甲基丙烯酸酯为交联剂,以聚丙烯酰胺和壳聚糖为原料,合成了一种新型创面敷料──半渗透网络水凝胶,以期实现抗生素的突释和生长因子的控制释放。此凝胶的水含量非常高(约80%),并且在创面基质pH范围内(pH4.0-7.0)膨胀性质稳定;并且该种材料载有抗生素哌拉西林-三唑巴坦,生长因子为EGF;创面敷用此敷料1h,血清哌拉西林-三唑巴坦浓度即可达到治疗量,可实现EGF的持续释放达 5天的时间之久。Choi等(Journal of biomedical materialsresearch. 2010;95(2):564-573)制备了一种用于糖尿病性溃疡的创面黏附性感温水凝胶,将甲基丙烯酸缩水甘油酯化壳寡糖,二丙烯酰普朗尼克和 rhEGF共混制得物理交联水凝胶,再经光照射制得化学交联凝胶;小鼠背部烧伤创面敷用溶液状态的物理交联凝胶80μL(含1μg rhEGF),光照30s使其发生化学交联,再覆以医用绷带;研究结果表明,包封 rhEGF的水凝胶可提高创面的局部rhEGF浓度,维持角蛋白细胞的分化,从而促进难愈性创面的愈合。在上述一系列研究中,水凝胶是一种主要的有效成分。它作为一种高分子聚合物,性能优于传统敷料和生物敷料,其中的亲水集团使得水凝胶本身具体强大的吸水能力,吸水过后,水凝胶发生膨胀,与水分子牢固结合并保存,可以在吸收创面渗液的同时,具备一定保湿能力。水凝胶高分子交联形成的三维网状结构,使得其除了自身固有的特点之外,还可以成为某些特定药物的载体,发挥药物的功能。另一方面,多种研究表明,水凝胶的有机成分,具有改善创面微环境的能力,可以有效促进创面愈合。Synthetic materials have long been found to help promote healing of skin wounds. In 1962, Dr. Winter of the University of London published a famous paper in the journal Nature, demonstrating the healing effect of moist environment on wounds: the probability of re-epithelialization of air-exposed wounds compared with sealing porcine tomographic skin defect wounds with polyethylene film 50% increase (Nature. 1962; 193:293-4). (Polymer edition. 2013; 24(7): 807-819) synthesized a novel wound dressing- ─Semi-permeable network hydrogels to achieve burst release of antibiotics and controlled release of growth factors. The water content of this gel is very high (about 80%) and the swelling properties are stable in the pH range of the wound matrix (pH 4.0-7.0); and this material is loaded with antibiotics piperacillin-tazobactam, growth factors It is EGF; when the dressing is applied to the wound for 1 hour, the serum piperacillin-tazobactam concentration can reach the therapeutic amount, and the sustained release of EGF can be achieved for 5 days. Choi et al. (Journal of biomedical materials research. 2010; 95(2): 564-573) prepared a wound-adhesive warm hydrogel for diabetic ulcers by esterifying glycidyl methacrylate with chitosan oligosaccharide, dipropylene Physically cross-linked hydrogel was prepared by blending acyl pluronic and rhEGF, and then chemically cross-linked gel was prepared by light irradiation; 80 μL of physical cross-linked gel (containing 1 μg rhEGF) was applied to the back burn wound of mice , 30s of light to make it chemically cross-linked, and then covered with medical bandages; the results show that the hydrogel encapsulating rhEGF can increase the local rhEGF concentration in the wound, maintain the differentiation of keratinocytes, and promote the healing of refractory wounds . In the above series of studies, hydrogel was a major active ingredient. As a high molecular polymer, its performance is better than that of traditional dressings and biological dressings. The hydrophilic group in it makes the hydrogel itself specific and strong water absorption capacity. After water absorption, the hydrogel swells and is firmly combined with water molecules and preserved. , can absorb wound exudate at the same time, has a certain moisturizing ability. The three-dimensional network structure formed by the cross-linking of hydrogel macromolecules makes it, in addition to its own inherent characteristics, also can become the carrier of some specific drugs and exert the function of drugs. On the other hand, various studies have shown that the organic components of hydrogels have the ability to improve the microenvironment of the wound and can effectively promote wound healing.
然而水凝胶也存在很多不足。比如,水凝胶置于创面后,身体肌肉的运动易导致胶体的损坏甚至破裂,增加感染风险,同时也破坏水凝胶结构,影响其功能。除此之外,水凝胶本身也不具备抗菌性,无法抵御细菌的入侵,因此存在感染的风险。长期使用水凝胶之后,水凝胶因强大的吸水能力而发生肿胀,与创面贴合较差。另外,应用于烧伤创面的理想水凝胶剂需达到更高要求:自动修复敷料损坏,具备应变性;搭载部分药物,防止创面感染,具备抗菌性;状态可改变,具备长时间的贴合性;释放某种促进创面愈合的药物等;然而目前临床并没有能共同达到上述特性的水凝胶。However, hydrogels also have many shortcomings. For example, after the hydrogel is placed on the wound, the movement of the body muscles can easily lead to damage or even rupture of the colloid, increasing the risk of infection, and also destroying the structure of the hydrogel and affecting its function. In addition, the hydrogel itself is not antibacterial and cannot resist the invasion of bacteria, so there is a risk of infection. After long-term use of the hydrogel, the hydrogel swells due to its strong water absorption capacity, and the adhesion to the wound surface is poor. In addition, the ideal hydrogel applied to burn wounds needs to meet higher requirements: it can automatically repair the damage of the dressing and has adaptability; it carries some drugs to prevent wound infection and has antibacterial properties; the state can be changed, and it has long-term fit. ; release a drug that promotes wound healing, etc.; however, there is currently no hydrogel that can achieve the above characteristics in clinical practice.
因此能否通过聚合的方法生产出一种水凝胶,在保证吸水性、保湿性的基础上,还可自动修复敷料损坏,具备应变性;搭载部分药物,防止创面感染,具备抗菌性;状态可改变,具备长时间的贴合性;同时,释放某种促进创面愈合的药物;这成为了一个值得研究的技术问题。另外,制备除具有以上性能的水凝胶之外,能否制备出具有温敏特性、可自我修复的新型水凝胶材料,成为本发明亟待解决的技术问题。Therefore, whether a hydrogel can be produced by means of polymerization, on the basis of ensuring water absorption and moisturizing properties, it can also automatically repair the damage of the dressing, and has flexibility; it can carry some drugs to prevent wound infection and has antibacterial properties; state It can be changed and has a long-term fit; at the same time, it releases a drug that promotes wound healing; this has become a technical problem worthy of study. In addition, in addition to the preparation of hydrogels with the above properties, whether a new type of hydrogel material with temperature-sensitive properties and self-healing can be prepared has become a technical problem to be solved urgently in the present invention.
发明内容SUMMARY OF THE INVENTION
本发明的目的就是为了解决上述技术问题,而提供一种具有温度响应的三嵌段水凝胶共聚物及其制备方法。本发明提供的水凝胶共聚物可用于烧伤创面的快速愈合,其具有生物组织粘合性和抗菌性,能根据临床需求搭载不同的药物,同时其具有温敏特性,方便进行储存和运输,并有益于手术使用如采用喷涂或注射使用。The purpose of the present invention is to solve the above technical problems, and provide a temperature-responsive triblock hydrogel copolymer and a preparation method thereof. The hydrogel copolymer provided by the invention can be used for the rapid healing of burn wounds, has biological tissue adhesion and antibacterial properties, can carry different drugs according to clinical needs, and has temperature-sensitive properties, which is convenient for storage and transportation, And beneficial for surgical use such as spray or injection.
本发明的目的之一是提供一种具有温度响应的三嵌段水凝胶共聚物,其是由聚乙二醇单体和N-异丙基丙烯酰胺单体聚合而成的 ABA型三嵌段网状共聚物,所述共聚物包含贻贝仿生组织粘合基团和银纳米颗粒锚定基团,所述聚乙二醇的数均分子量为3000-5000;所述共聚物的分子结构式如式(Ⅰ)所示:One of the objectives of the present invention is to provide a temperature-responsive triblock hydrogel copolymer, which is an ABA-type triblock polymerized from polyethylene glycol monomer and N-isopropylacrylamide monomer. A segmented network copolymer, the copolymer comprises a mussel biomimetic tissue adhesion group and a silver nanoparticle anchoring group, the polyethylene glycol has a number average molecular weight of 3000-5000; the molecular structure of the copolymer is As shown in formula (I):
其中,所述x、y、z均为1~n的整数。Wherein, the x, y, and z are all integers from 1 to n.
其中,所述贻贝仿生组织粘合基团为多巴胺基团,所述银纳米颗粒锚定基团为巯基。所述聚乙二醇单体与N-异丙基丙烯酰胺单体的质量比为1~2:2~3。Wherein, the mussel biomimetic tissue adhesion group is a dopamine group, and the silver nanoparticle anchoring group is a sulfhydryl group. The mass ratio of the polyethylene glycol monomer to the N-isopropylacrylamide monomer is 1-2:2-3.
本发明提供的上述水凝胶共聚物的结构具有如下特点:The structure of the above-mentioned hydrogel copolymer provided by the invention has the following characteristics:
1)本发明的水凝胶材料含有温敏响应基团,能够赋予水凝胶良好的温度响应性能,在常温或是低于体温条件下呈液体状态,在体温或是接触体表的时候转变为凝胶状态,方便于其储存运输,并且有益于手术使用如采用喷涂或注射使用;1) The hydrogel material of the present invention contains a temperature-sensitive responsive group, which can endow the hydrogel with good temperature-responsive performance. It is in a liquid state at room temperature or below body temperature, and changes at body temperature or when it contacts the body surface. In a gel state, it is convenient for storage and transportation, and it is beneficial for surgical use such as spraying or injection;
2)贻贝仿生组织粘合基团(多巴胺基团),已经被证明可以赋予制备的粘合剂对生物组织良好的粘接性,该基团的引入可以保证水凝胶在使用过程中对烧伤组织良好的附着力;2) The mussel biomimetic tissue adhesive group (dopamine group) has been proven to endow the prepared adhesive with good adhesion to biological tissues. Good adhesion to burned tissue;
3)纳米颗粒锚定基团(巯基),该基团的引入可使水凝胶与银纳米颗粒之间进行有机的动态键结合,进一步提高银纳米颗粒复合水凝胶的强度,同时具备良好的抗菌性。在低温条件下,将该水凝胶与 CsA(环孢素A)和银纳米粒子按照实验条件需求制备出具有合适浓度的水溶液,该溶液可以通过喷涂或注射使用与烧伤伤口处,通过伤口处的温度变化形成水凝胶保护层。3) Nanoparticle anchoring group (thiol group), the introduction of this group can make organic dynamic bond between the hydrogel and silver nanoparticles, further improve the strength of silver nanoparticle composite hydrogel, and at the same time have good performance. of antibacterial properties. Under low temperature conditions, the hydrogel, CsA (cyclosporine A) and silver nanoparticles were prepared according to the experimental conditions to prepare an aqueous solution with a suitable concentration. The solution can be applied to the burn wound by spraying or injection. The temperature change forms a hydrogel protective layer.
本发明提供的上述水凝胶材料具有高度应变性、生物相容性、粘合性、热敏性、可注射性和抗微生物性等特性。该水凝胶在低温或是室温下可以实现有效的溶胶凝胶转变,该性能赋予这种材料良好的注射性和术后清理方便性,同时由于水凝胶中的主要成分为生物相容性良好的高分子材料如聚氧化乙烯(PEG),保证所得水凝胶材料对细胞有着优异的生物相容性。The above-mentioned hydrogel materials provided by the present invention have the characteristics of high strainability, biocompatibility, adhesiveness, heat sensitivity, injectability and antimicrobial properties. The hydrogel can achieve an effective sol-gel transition at low temperature or room temperature, and this performance endows the material with good injectability and ease of postoperative cleaning. At the same time, the main component of the hydrogel is biocompatibility Good polymer materials, such as polyethylene oxide (PEG), ensure that the obtained hydrogel materials have excellent biocompatibility with cells.
本发明的水凝胶可以通过缓释作用让烧伤伤口始终处于抗菌及 CsA给药的作用下。并且,由于该水凝胶存在儿茶酚氢键、pi-pi相互作用力及动态巯银键,因此该水凝胶材料将具备良好的自修复性能,这一性能可以保证伤口在外力损坏进行自我修复免于因伤口的裸露带来的伤害。The hydrogel of the present invention can keep the burn wound under the effect of antibacterial and CsA administration all the time through the sustained release effect. Moreover, due to the presence of catechol hydrogen bonds, pi-pi interaction force and dynamic mercapto-silver bonds in the hydrogel, the hydrogel material will have good self-healing properties, which can ensure that the wound can be damaged by external forces. Self-healing from damage caused by the nakedness of the wound.
本发明制备的水凝胶具有良好的自修复性能,对常见的E-coli 细菌具有优异的抗菌效果,同时对皮肤细胞明显防粘自清洁,同时该水凝胶的温度响应性使其使用方便,可以通过注射的方式进行。该水凝胶材料的力学强度可以通过改变贻贝仿生高分子材料中多巴胺的含量及其他组分的比例进行调节。The hydrogel prepared by the invention has good self-healing performance, excellent antibacterial effect on common E-coli bacteria, obvious anti-sticking and self-cleaning to skin cells, and the temperature responsiveness of the hydrogel makes it easy to use , can be carried out by injection. The mechanical strength of the hydrogel material can be adjusted by changing the content of dopamine and the ratio of other components in the mussel biomimetic polymer material.
本发明提供的上述水凝胶材料对烧伤创面具有明显的促愈作用,其中负载CsA和银颗粒后,CsA的局部释放有助于促进烧伤创面愈合以及减少烧伤局部炎症反应强度。研究表明本发明的水凝胶材料可以促进全层烧伤创面愈合速度,减少体内炎症因子释放、促进肉芽组织生长等作用。The above-mentioned hydrogel material provided by the present invention has an obvious effect of promoting the healing of burn wounds. After loading CsA and silver particles, the local release of CsA helps to promote the healing of burn wounds and reduce the intensity of local inflammatory response of burns. Studies have shown that the hydrogel material of the present invention can promote the healing speed of full-thickness burn wounds, reduce the release of inflammatory factors in the body, and promote the growth of granulation tissue.
本发明的目的之二是提供了上述具有温度响应的三嵌段水凝胶共聚物的制备方法,所述制备方法包括以下步骤:The second object of the present invention is to provide a preparation method of the above-mentioned temperature-responsive triblock hydrogel copolymer, the preparation method comprising the following steps:
(1)先将N-异丙基丙烯酰胺单体和聚乙二醇单体采用RAFT聚合法合成共聚物;(1) N-isopropylacrylamide monomer and polyethylene glycol monomer are firstly synthesized by RAFT polymerization method;
(2)然后将步骤(1)所得共聚物中的活性酯与与贻贝仿生组织粘合基团进行置换,向聚合物中引入贻贝仿生组织粘合基团;(2) then replace the active ester in the copolymer obtained in step (1) with the mussel biomimetic tissue adhesive group, and introduce the mussel biomimetic tissue adhesive group into the polymer;
(3)向步骤(2)所得物中加入巯基乙胺进行化学接枝反应,得到目标产物水凝胶共聚物。(3) adding mercaptoethylamine to the result of step (2) to carry out chemical grafting reaction to obtain the target product hydrogel copolymer.
与现有技术相比,本发明的有益效果如下:Compared with the prior art, the beneficial effects of the present invention are as follows:
本发明制备的水凝胶具有自我修复能力、抗微生物性和防污染性,能够很好作为烧伤创面愈合用的敷料,同时具有明显的温敏特性,其在常温或是低于体温条件下呈液体状态,在体温或是接触体表的时候转变为凝胶状态,方便于其储存运输,并且有益于手术使用如采用喷涂或注射使用。该水凝胶共聚物负载CsA和银纳米颗粒,可通过缓释让烧伤伤口始终处于抗菌及CsA给药的作用下,能够具备良好的自修复性能,保证伤口在外力损坏进行自我修复免于因伤口的裸露带来的伤害。同时该水凝胶可以促进全层烧伤创面愈合速度,减少体内炎症因子释放、促进肉芽组织生长等作用。The hydrogel prepared by the invention has self-healing ability, anti-microbial property and anti-pollution property, can be well used as a dressing for burn wound healing, and at the same time has obvious temperature-sensitivity characteristics. The liquid state changes to a gel state at body temperature or when it contacts the body surface, which is convenient for storage and transportation, and is beneficial for surgical use such as spraying or injection. The hydrogel copolymer is loaded with CsA and silver nanoparticles, which can keep the burn wound under the action of antibacterial and CsA administration through sustained release, and has good self-healing performance, ensuring that the wound can self-repair when damaged by external force Injury from the nudity of the wound. At the same time, the hydrogel can promote the healing speed of full-thickness burn wounds, reduce the release of inflammatory factors in the body, and promote the growth of granulation tissue.
附图说明Description of drawings
图1为本发明的水凝胶的结构示意图。FIG. 1 is a schematic structural diagram of the hydrogel of the present invention.
具体实施方式Detailed ways
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例对本发明进行具体描述,有必要指出的是,以下实施例仅仅用于对本发明进行解释和说明,并不用于限定本发明。本领域技术人员根据上述发明内容所做出的一些非本质的改进和调整,仍属于本发明的保护范围。In order to make the purpose, technical solutions and advantages of the present invention clearer, the present invention will be described in detail below with reference to the examples. It is necessary to point out that the following examples are only used to explain and illustrate the present invention, and are not intended to limit the present invention. . Some non-essential improvements and adjustments made by those skilled in the art based on the above-mentioned contents of the invention still belong to the protection scope of the present invention.
实施例1Example 1
一种具有温度响应的三嵌段水凝胶共聚物,其是由聚乙二醇单体和N-异丙基丙烯酰胺单体聚合而成的ABA型三嵌段网状共聚物,所述共聚物包含贻贝仿生组织粘合基团和银纳米颗粒锚定基团,其分子结构式如下:A temperature-responsive tri-block hydrogel copolymer is an ABA-type tri-block network copolymer polymerized from polyethylene glycol monomers and N-isopropylacrylamide monomers, and the The copolymer contains mussel biomimetic tissue adhesion groups and silver nanoparticle anchoring groups, and its molecular structure is as follows:
该水凝胶共聚物具有明显的温敏特性(如图1),其在常温或是低于体温条件下呈液体状态,在体温或是接触体表的时候转变为凝胶状态,方便于其储存运输,并且有益于手术使用如采用喷涂或注射使用。The hydrogel copolymer has obvious temperature-sensitive properties (as shown in Figure 1), it is in a liquid state at room temperature or below body temperature, and changes into a gel state when it is at body temperature or in contact with the body surface, which is convenient for its Storage and transportation, and beneficial for surgical use such as spray or injection.
该水凝胶的制备方法参考“ACS applied materials&interfaces. 2017;9(11):9221-9225”中的方法,具体为:The preparation method of the hydrogel refers to the method in "ACS applied materials & interfaces. 2017; 9(11):9221-9225", specifically:
(1)先将N-异丙基丙烯酰胺单体和聚乙二醇单体采用RAFT聚合法合成共聚物;聚合反应过程中加入交联剂甲叉双丙烯酰胺、引发剂过硫酸铵和催化剂二硫代氨基甲酸酯;(1) First, the N-isopropylacrylamide monomer and the polyethylene glycol monomer are synthesized by RAFT polymerization method; in the polymerization process, the crosslinking agent methylenebisacrylamide, the initiator ammonium persulfate and the catalyst are added Dithiocarbamates;
(2)然后将步骤(1)所得共聚物中的活性酯与贻贝仿生组织粘合基团进行置换,向聚合物中引入贻贝仿生组织粘合基团;(2) then replacing the active ester in the copolymer obtained in step (1) with the mussel biomimetic tissue adhesion group, and introducing the mussel biomimetic tissue adhesion group into the polymer;
(3)向步骤(2)所得物中加入巯基乙胺进行化学接枝反应,得到目标产物水凝胶共聚物。(3) adding mercaptoethylamine to the result of step (2) to carry out chemical grafting reaction to obtain the target product hydrogel copolymer.
其中聚乙二醇的数均分子量为3000-5000,聚乙二醇单体与N- 异丙基丙烯酰胺单体的质量比为1~2:2~3。The number average molecular weight of polyethylene glycol is 3000-5000, and the mass ratio of polyethylene glycol monomer to N-isopropylacrylamide monomer is 1-2:2-3.
实验例1Experimental example 1
构建大鼠重度烧伤模型,将实施例1所得水凝胶材料(以聚乙二醇单体与N-异丙基丙烯酰胺单体的质量比1:3为例,聚乙二醇的数均分子量为3000)用于烧伤后的修复,探讨实施例1所得水凝胶材料对于烧伤后大鼠局部组织恢复的保护作用和全身炎症反应的抑制作用,其方法如下:A rat model of severe burn was constructed, and the hydrogel material obtained in Example 1 (taking the mass ratio of polyethylene glycol monomer to N-isopropylacrylamide monomer 1:3 as an example, the number average of polyethylene glycol Molecular weight is 3000) is used for the repair after burn, to explore the protective effect of the hydrogel material obtained in Example 1 on the recovery of local tissue in rats after burn and the inhibitory effect of systemic inflammatory response, and the methods are as follows:
取40只大鼠,分为4组,对照组(Control)、模型组(Burn)、阳性对照组(Burn+Intrasite Gel)、实验组(Burn+HydrogelA)。全部大鼠于背部剃毛,用1%戊巴比妥钠1mL腹腔注射进行全麻,取面积为30%总体表面积(TBSA=K*W*0.5,K=0.9,W为小鼠体重)为烧伤面积。除对照组外全部大鼠麻醉后于99摄氏度的水中烫伤15秒,对照组大鼠麻醉后于37摄氏度的水中温浴15秒。40 rats were taken and divided into 4 groups, control group (Control), model group (Burn), positive control group (Burn+Intrasite Gel), experimental group (Burn+HydrogelA). All rats were shaved on the back, and 1 mL of 1% sodium pentobarbital was injected intraperitoneally for general anesthesia, and the area was taken as 30% of the total surface area (TBSA=K*W*0.5, K=0.9, W is the weight of the mouse): burn area. All rats except the control group were anesthetized and scalded in water at 99 degrees Celsius for 15 seconds, while rats in the control group were warmed in water at 37 degrees Celsius for 15 seconds after anesthesia.
烧伤后1d处理创面。实验组,创面用本发明搭载CsA的新型水凝胶敷料处理;阳性对照组,创面用清得佳(Intrasite Gel,一种临床常用水凝胶敷料)处理;模型组不给药,其余处理一致。在大鼠麻醉后,背部以洗必泰清洗消毒后,按照分组情况给药,给药厚度为3~5mm,防止药品脱落。在烧伤后3、7、10、14d,采用Image Pro Plus软件测量并记录创面愈合过程、计算痂面面积、创面愈合率、完全愈合时间,观察创面形态变化。Wounds were treated 1 day after burn. In the experimental group, the wounds were treated with the novel hydrogel dressing carrying CsA according to the present invention; in the positive control group, the wounds were treated with Intrasite Gel (a hydrogel dressing commonly used in clinical practice); the model group was not given any medication, and the other treatments were the same. . After the rats were anesthetized, the backs were cleaned and disinfected with chlorhexidine, and the drugs were administered according to the grouping conditions, with a thickness of 3-5 mm to prevent the drugs from falling off. At 3, 7, 10, and 14 days after burn, Image Pro Plus software was used to measure and record the wound healing process, calculate the scab surface area, wound healing rate, and complete healing time, and observe the morphological changes of the wound.
统计实验结果如表1所示:The statistical test results are shown in Table 1:
表1Table 1
实验例2Experimental example 2
将“ACS applied materials&interfaces.2017;9(11):9221-9225”中制得的水凝胶用于上述大鼠重度烧伤模型,记为阳性对照组2,通过负载CsA,与本发明实验组相比,结果如表2:The hydrogel prepared in "ACS applied materials & interfaces. 2017; 9(11): 9221-9225" was used in the above-mentioned severe burn model of rats, and recorded as positive control group 2. By loading CsA, it was similar to the experimental group of the present invention. The results are shown in Table 2:
表2Table 2
实验例3Experimental example 3
在烧伤后3、7、10、14d,采用尾静脉采血,分别在各个时间点取4组大鼠血液,离心得血清,使用Varioskan Flash多功能酶标仪以及ELISA试剂盒,检测IL-6和TNF-α水平。On the 3rd, 7th, 10th, and 14th days after the burn, blood was collected from the tail vein. The blood of 4 groups of rats was collected at each time point, and the serum was obtained by centrifugation. TNF-α levels.
所得结果如表3和4所示:The results obtained are shown in Tables 3 and 4:
表3table 3
表4Table 4
同时在烧伤后14天,取创面组织,分别检测创面肉芽组织之间结构组织变化,胶原的分布以及EFG-2的表达情况。At the same time, 14 days after burn, the wound tissue was collected to detect the structural changes between the granulation tissues, the distribution of collagen and the expression of EFG-2.
上述实验结果表明,携带CsA的新型水凝胶敷料可以发挥促进全层烧伤创面的愈合,提高愈合速度,减少体内炎症因子释放、促进内皮细胞生长等作用。The above experimental results show that the new hydrogel dressing carrying CsA can promote the healing of full-thickness burn wounds, improve the healing speed, reduce the release of inflammatory factors in the body, and promote the growth of endothelial cells.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010587547.1A CN111658819A (en) | 2020-06-24 | 2020-06-24 | Triblock hydrogel copolymer with temperature response and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010587547.1A CN111658819A (en) | 2020-06-24 | 2020-06-24 | Triblock hydrogel copolymer with temperature response and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111658819A true CN111658819A (en) | 2020-09-15 |
Family
ID=72389755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010587547.1A Pending CN111658819A (en) | 2020-06-24 | 2020-06-24 | Triblock hydrogel copolymer with temperature response and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111658819A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101664563A (en) * | 2009-09-21 | 2010-03-10 | 杭州国纳科技有限公司 | Preparation method of anti-bacterial hydrogel dressing |
| US20170190844A1 (en) * | 2016-01-06 | 2017-07-06 | The Governors Of The University Of Alberta | Hydrogel |
| CN107522875A (en) * | 2016-06-20 | 2017-12-29 | 中国科学院宁波材料技术与工程研究所 | Hydrogel, its preparation method and the application of Nano silver grain crosslinking |
| CN108929412A (en) * | 2018-07-10 | 2018-12-04 | 南昌大学 | A kind of preparation method of the adhesiveness injection aquagel of temperature-responsive |
-
2020
- 2020-06-24 CN CN202010587547.1A patent/CN111658819A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101664563A (en) * | 2009-09-21 | 2010-03-10 | 杭州国纳科技有限公司 | Preparation method of anti-bacterial hydrogel dressing |
| US20170190844A1 (en) * | 2016-01-06 | 2017-07-06 | The Governors Of The University Of Alberta | Hydrogel |
| CN107522875A (en) * | 2016-06-20 | 2017-12-29 | 中国科学院宁波材料技术与工程研究所 | Hydrogel, its preparation method and the application of Nano silver grain crosslinking |
| CN108929412A (en) * | 2018-07-10 | 2018-12-04 | 南昌大学 | A kind of preparation method of the adhesiveness injection aquagel of temperature-responsive |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Biodegradable gelatin/silver nanoparticle composite cryogel with excellent antibacterial and antibiofilm activity and hemostasis for Pseudomonas aeruginosa-infected burn wound healing | |
| Cao et al. | Antibacterial and antioxidant wound dressings with pH responsive release properties accelerate chronic wound healing | |
| Rezvani Ghomi et al. | Wound dressings: Current advances and future directions | |
| Chopra et al. | Strategies and therapies for wound healing: a review | |
| Shi et al. | Recent progresses of collagen dressings for chronic skin wound healing | |
| Kim et al. | Development of polyvinyl alcohol–sodium alginate gel-matrix-based wound dressing system containing nitrofurazone | |
| Sung et al. | Gel characterisation and in vivo evaluation of minocycline-loaded wound dressing with enhanced wound healing using polyvinyl alcohol and chitosan | |
| US5834007A (en) | Wound-covering material and wound-covering composition | |
| Gu et al. | Research progress related to thermosensitive hydrogel dressings in wound healing: a review | |
| RU2422133C1 (en) | Hydrophylic gel, method of its obtaining (versions), wound covering and based on it bandage means | |
| Dong et al. | Poly (N-isopropyl-acrylamide)/poly (γ-glutamic acid) thermo-sensitive hydrogels loaded with superoxide dismutase for wound dressing application | |
| CN111718451A (en) | A kind of hydrogel material with self-healing performance and its preparation method and application | |
| BRPI0717734B1 (en) | METHOD FOR PREPARING A DRY POWDER FROM POLYMERIC NANOParticles, DRY POWDER AND USE | |
| CN105228658B (en) | A kind of medical dressing hydrogel compound fabric and its preparation method and application | |
| JPWO1995007719A1 (en) | Wound covering material and wound covering composition | |
| CN111643720A (en) | Hydrogel with antibacterial property for healing burn wound and preparation method thereof | |
| US10322185B2 (en) | Controlled release carrier for drugs containing silk fibroin porous material | |
| CN113214507B (en) | Preparation method of antibacterial glycopeptide hydrogel | |
| CN115975224B (en) | A pH/ROS dual-response tissue-adhesive drug-loaded hydrogel and its preparation method and application | |
| CN112999412A (en) | Hydrogel dressing for wound healing and preparation method thereof | |
| CN118852487A (en) | An antimicrobial peptide polymer and its preparation method and application | |
| CN118718076A (en) | A nanocomposite hydrogel dressing and preparation method thereof | |
| CN111073001A (en) | A kind of amphoteric glucan hydrogel and application | |
| CN104784744A (en) | Compound method for preparing wound dressing by utilizing human hair keratin | |
| Ding et al. | A temperature-sensitive hydrogel loaded with taxifolin promotes skin repair by modulating MAPK-mediated autophagic pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200915 |
|
| RJ01 | Rejection of invention patent application after publication |